Free Event: Melanoma > Exchange Patient & Advocate Forum
Join MRA on February 26, 2020 for an exciting half-day conference to learn about cutting-edge advances in melanoma, the research pipeline, and the latest in melanoma prevention and early detection.
Approaches to Neoadjuvant Treatment in Melanoma: A Public Workshop Organized by the FDA and MRA
On November 6, 2019, the FDA and the Melanoma Research Alliance co-hosted a public workshop to identify, discuss, and address key issues, challenges and opportunities in the pursuit of neoadjuvant therapies for patients with surgically resectable melanoma. This exciting, half-day workshop brought together clinicians, researchers, regulators, and patient advocates to explore opportunities and discuss challenges in the development of neoadjuvant therapies for melanoma. The workshop took place at National Harbor (outside of Washington, D.C.) with opportunities to participate in person and via simultaneous webcast.
Highlights from the 2019 Scientific Retreat
Over the course of three days, MRA convened over 300 people from across the melanoma research community: patients, doctors, researchers, industry, and government. Participants discussed everything from new treatment approaches such as RNA-based vaccines, strategies to fight back against treatment resistance, and hurdles to testing neo-adjuvant therapies in melanoma.
Building Community While Raising More than $10 Million for Melanoma
Leveraged Finance Fights Melanoma has become an annual event that brings over 1,000 people together from the leveraged finance and private equity community. Cofounder Brendan Dillon shares his own journey with melanoma.
Leveraged Finance Community Comes Together to Fight Melanoma
On May 23, 2018 more than one thousand professionals from the leveraged finance and finance community at-large will come together in the fight against melanoma for the seventh annual Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party. The event, held each year in the Rockefeller Center’s summer garden, has raised over $8.6 million to advance the Melanoma Research Alliance’s global research programs.
MRA Raises Millions of Dollars for Groundbreaking Melanoma Research
Normally, when people are at a Sotheby’s auction, they come to bid on beautiful and rare art. On Nov. 2nd, however, more than 240 people came together at Sotheby’s Headquarters in New York City to raise their paddle in the fight against melanoma. Together, participants raised over $20 million to further advance melanoma research.
LFFM Fundraising Event Again Reaches a Record Setting Year
Nearly 1,000 professionals from the leveraged finance community gathered for the sixth annual Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party raising a record $1.8 million in funds for the Melanoma Research Alliance (MRA), the largest private funder of melanoma research.
Finance Industry Rallies to Fight Melanoma
Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event, sponsored annually in New York City by the Melanoma Research Alliance (MRA) has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities – all gathered together in response to melanoma.
Spotlight on MRA’s Ninth Annual Scientific Retreat
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 28 February 2017 In Allies & Partnerships, Events, Science
In mid-February, MRA held its premiere research event — the 9th Annual Scientific Retreat, in Washington, DC. A total of 297 individuals registered for the meeting representing a spectrum of key stakeholders in melanoma including academic investigators, pharmaceutical and biotech company representatives, melanoma advocates from various different non-profit organizations, donors and government officials.
Melanoma Prevention: The Latest Advances & Future Directions
During my interview with Susan Swetter, MD, Professor of Dermatology,
Stanford University and VA Palo Alto, at the Melanoma Research Alliance Ninth Annual Scientific Retreat in Washington, DC, I inquired about the Panel Discussion she was part of titled: News from the field: What’s going well and what remains to be done?